$NVSBearishLow

Swiss Market Ends Sharply Lower

Switzerland’s SMI fell sharply on Monday, closing at 13,305.40 (-1.75%, -237.26 points) as hopes for a U.S.-Iran peace deal faded. Iran’s Tasnim said Tehran would halt talks and close the Strait of Hormuz, citing U.S. ceasefire violations; U.S. Central Command said it carried out self-defense strikes on Iranian drone-related sites. Roche and Novartis dropped 3.61% and 3.33%. Swiss retail sales rose 1.6% y/y in April, while Q1 GDP grew 0.4% (revised down from 0.5%).

7/10
4/10
Low
Bearish
at the close (Monday) after new U.S.-Iran ceasefire/talks headlines
risk-off broad selloff across Swiss large caps; mixed relative strength in select names

Risk-off pressure on Swiss large-cap pharma; likely correlates with SMI drawdown.

Novartis ended down 3.33% during the Swiss market selloff tied to U.S.-Iran ceasefire violations.

Limited single-name edge unless escalation worsens or pharma-specific flows emerge.

Background

The selloff is linked to renewed U.S.-Iran tensions: Tehran accuses the U.S. of violating a ceasefire; reports say talks may halt and the Strait of Hormuz could be closed.

Why it matters

The immediate tradable signal is broad equity risk reduction across Switzerland, with pharma and cyclicals notably down; macro data provides additional pressure via a downgraded growth outlook.

Market relevance

This is primarily a geopolitics-driven risk-off tape for Swiss equities, with macro prints reinforcing uncertainty.

Market effects

Geopolitical escalation (Strait of Hormuz closure risk) raises energy/uncertainty premium, pressuring broad Swiss equities; defensives still sold.

SMI closed down 1.75%, indicating Switzerland-wide de-risking tied to Middle East developments and softer growth outlook.

U.S.-Iran escalation risk can spill into European risk assets and energy/commodity expectations globally.

Alternative perspectives

Some Swiss names (e.g., Logitech, Kuehne+Nagel, UBS) outperformed, suggesting flows/hedging may be offsetting pure geopolitics beta.

The article also cites Swiss macro prints (retail sales beat; GDP revised down; growth outlook downgraded), which can compound or partially offset the geopolitical driver.

Key entities

  • SMI

    Swiss benchmark index ended down 1.75% on the session.

  • Swiss Federal Statistical Office

    Reported Swiss retail sales growth accelerating in April.

  • SECO

    Reported Q1 GDP growth revised down and downgraded 2026 growth outlook.

  • Tasnim

    State-affiliated outlet cited for claims about halting talks and Strait of Hormuz closure.

  • U.S. Central Command

    Cited for conducting self-defense strikes on Iranian radar/command sites.

Related articles

$TMMed

10 Best Cheap Stocks to Buy for Beginners

Goldman Sachs’ Ben Snider told CNBC that markets are focused on near-term visible earnings; he expects S&P 500 earnings growth of 24% this year and 13% next year, with AI infrastructure beneficiaries driving about half. The article screens for stocks with forward P/E <15 and high hedge-fund popularity (Insider Monkey, Q1 2026). It lists Toyota (sales down 3.1% YoY in April) and Novartis (Cosentyx Phase 3 REPLENISH PMR data).

$NVSLow

Swiss Market Ends On Strong Note

Swiss stocks ended higher on Thursday after a cautious start. The SMI rose 0.93% to close at 13,341.27 (intraday high 13,395.00). Roche gained 4.2% after developing a research-use-only PCR test for the rare Ebola Bundibugyo virus. Partners Group rose 3.73%; Novartis, Alcon, Sonova and SGS gained 1.6%-2%. Switzerland’s unemployment rate held at 3% in May, SECO said.

$NVSMedAI 9/10

Novartis Cosentyx Shows Sustained Remission In Polymyalgia Rheumatica

Novartis said Phase III REPLENISH trial results for Cosentyx in polymyalgia rheumatica, published in the New England Journal of Medicine and presented at EULAR 2026, showed about twice as many patients achieved sustained remission versus placebo and had significant steroid reductions. The trial met primary/secondary endpoints for both 150 mg and 300 mg arms through week 52, with no new safety signals. Novartis filed for regulatory review in the U.S., EU and Japan.

$NVSMedAI 9/10

Novartis Vanrafia Data Show Clinically Meaningful Kidney Protection In IgA Nephropathy

Novartis reported final Phase III ALIGN results for Vanrafia in adults with IgA nephropathy. According to the company, over 2.5 years Vanrafia cut the rate of kidney function decline by about 34% vs placebo and sustained lower proteinuria. In 340 patients, the annualized eGFR slope was -2.7 vs -4.1, and proteinuria fell 38.3% at nine months. Safety was similar to placebo; Novartis plans traditional approval submissions for 2026.